Some investors have responded to FBT’s durability. In the second quarter, FBT was the only one of the five biotech ETFs to see capital flow in as the fund added $50 million in new assets. Since the start of the third quarter, FBT has added $8 million in new assets, making it one of just two biotech ETFs to see inflows this quarter.

Investors that want some exposure to FBT without the commitment of owning the fund outright can acquire a partial positon in the fund via the First Trust Dorsey Wright Focus 5 Fund (NasdaqGM: FV).

FV holds five other First Trust sector funds with FBT being the largest weigh at 22.1%. The First Trust Health Care AlphaDEX Fund (NYSEArca: FXH), FV’s second-largest holding at over 20%, allocates nearly 15% of its weight to biotech stocks, indicating investors can use FV to gain solid biotech exposure without making a full bet on an individual stock or dedicated biotech ETF. [Momentum Rebound for This ETF]

First Trust NYSE Arca Biotechnology Index Fund